172 related articles for article (PubMed ID: 19381033)
21. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
22. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
23. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
24. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
25. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 measurements in clinical oncology.
Reed E
N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
[No Abstract] [Full Text] [Related]
27. [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer].
Han XP; Zhang X
Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(30):2115-8. PubMed ID: 21029626
[TBL] [Abstract][Full Text] [Related]
28. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer.
Takenaka T; Yoshino I; Kouso H; Ohba T; Yohena T; Osoegawa A; Shoji F; Maehara Y
Int J Cancer; 2007 Aug; 121(4):895-900. PubMed ID: 17417781
[TBL] [Abstract][Full Text] [Related]
29. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.
Chen S; Zhang J; Wang R; Luo X; Chen H
Lung Cancer; 2010 Oct; 70(1):63-70. PubMed ID: 20541281
[TBL] [Abstract][Full Text] [Related]
30. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
31. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
[TBL] [Abstract][Full Text] [Related]
32. DNA repair by ERCC1 in non-small-cell lung cancer.
Cecere F; Bria E; Rosell R
N Engl J Med; 2006 Dec; 355(24):2590-1; author reply 2591. PubMed ID: 17167144
[No Abstract] [Full Text] [Related]
33. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
34. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
[TBL] [Abstract][Full Text] [Related]
35. [The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].
Hirai Y; Shimizu Y; Oura S; Yoshimasu T; Ota F; Nakamura R; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
Gan To Kagaku Ryoho; 2012 Mar; 39(3):381-4. PubMed ID: 22421763
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
Dunant A; Pignon JP; Le Chevalier T
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5017s-5021s. PubMed ID: 16000606
[TBL] [Abstract][Full Text] [Related]
38. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
[TBL] [Abstract][Full Text] [Related]
39. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
Wachters FM; Wong LS; Timens W; Kampinga HH; Groen HJ
Lung Cancer; 2005 Nov; 50(2):211-9. PubMed ID: 16169122
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
